
## Supplementary table 1. Prognostic factors for overall survival (OS) and disease-free survival

(DFS) in univariate cox analysis.


Influencing factors	DFS		OS	
	HR (95%CL)	Р	HR(95%CL)	Р
		value		value
Clinical stage	2.599(1.509-4.478)	0.001	3.156(1.736-5.738)	< 0.001
Age	0.489(0.237-1.009)	0.053	0.673(0.317-1.427)	0.301
Menstrual	0.995(0.489-2.023)	0.988	1.315(0.627-2.755)	0.469
status				
ER	0.568(0.286-1.128)	0.106	0.422(0.203-0.879)	0.018
PR	0.473(0.237-0.944)	0.034	0.368(0.173-0.782)	0.009
HER-2	3.977(1.990-7.947)	< 0.001	5.398(2.601-11.200)	< 0.001
Thrombosis	2.680(1.332-5.395)	0.006	2.993(1.420-6.310)	0.004
SBR grading	3.204(1.712-5.997)	< 0.001	3.904(1.982-7.687)	< 0.001
Ki67	2.119(1.042-4.311)	0.038	2.556(1.163-5.617)	0.019
Adjuvant	1.115(0.460-2.702)	0.809	0.923(0.376-2.270)	0.862
chemotherapy				0.002

Cancer Immunology, Immunotherapy (submitted in 2014) - Haiming Yu et al.



Supplementary figure1 Positive control and negative controls for rabbit anti-human CTLA-4 IgG. (A) Sections of human tonsil biopsy specimens with confirmed high expression of CTLA-4 molecules served as **positive control**; (B) Positive immunostaining for CTLA-4 in breast cancer cells; (C) Sections of breast cancer specimens incubated with the primary antibody diluent with no primary antibody were used as the **negative control 1**; (D) Sections of breast cancer specimens incubated with primary antibody (1:100 dilution, bs-1179R, Beijing Biosynthesis Biotechnology Co., Ltd, China) premixed with CTLA-4 peptide (bs-1179P, Beijing Biosynthesis Biotechnology Co., Ltd, China) were used as the **negative control 2**.


Cancer immunology, immunotherapy (submitted in 2014) – Haiming Yu et al.



Supplementary figure2 Examples for CTLA-4 staining intensities. (A) Tumor cell staining

intensity score 1. (B) Tumor cell staining intensity score 0.

Cancer immunology, immunotherapy (submitted in 2014) – Haiming Yu et al.



**Supplementary figure 3** Receiver operator characteristic (ROC) curves of CTLA-4 expression for overall survival in breast cancer patients. (A) Tumor CTLA-4 expression: sensitivity=51.7%; specificity=67.3%; area under the curve=0.537; SE=0.069; (B) Density of interstitial CTLA-4<sup>+</sup> lymphocytes: sensitivity=63.4%; specificity=69%; area under the curve=0.695; SE=0.058.

Cancer Immunology, Immunotherapy (submitted in 2014) - Haiming Yu et al.